Background Trastuzumab, a HER2 monoclonal antibody, has transformed the prognosis of
patients with the aggressive HER2-positive breast cancer type. Trastuzumab augments the …

Aim The combination of anthracyclines (AC) and trastuzumab (TRZ) is highly effective in
patients with aggressive HER‐2+ breast cancer, but has a significant risk of cardiotoxicity …

Background Trastuzumab improves dramatically the prognosis of HER2‐positive breast
cancer patients, but it may lead to cardiotoxicity with left ventricular (LV) systolic dysfunction …

Background Patients treated with anthracyclines and trastuzumab are at increased risk of
developing heart failure. Early diagnosis and treatment may prevent irreversible left …

Background Adjuvant trastuzumab improved overall survival and reduced the risk for
disease recurrence in women with breast cancers, because of its potential cardiotoxicity …

Objectives: This study determined the effects of doxorubicin and/or trastuzumab on diastolic
function and the relationship between diastolic function and systolic dysfunction …

Aims We aimed to determine the early changes and predictive value of left ventricular (LV)
segmental strain measures in women with breast cancer receiving doxorubicin. Methods …

Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Objective Recent studies in breast cancer patients and Trastuzumab therapy (Herceptin)
showed a development of a toxic cardiomyopathy as a severe complication. The aim of this …

BACKGROUND: Assessment of left ventricular systolic function is necessary during
trastuzumab-based chemotherapy because of potential cardiotoxicity. Deformation indices …